NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free RCKT Stock Alerts $26.94 -0.31 (-1.14%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$26.63▼$27.3050-Day Range$26.52▼$30.7452-Week Range$14.89▼$32.53Volume498,831 shsAverage Volume776,195 shsMarket Capitalization$2.44 billionP/E RatioN/ADividend YieldN/APrice Target$54.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rocket Pharmaceuticals alerts: Email Address Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.4% Upside$54.00 Price TargetShort InterestBearish11.31% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.52Based on 14 Articles This WeekInsider TradingSelling Shares$9.22 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.94) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector193rd out of 938 stocksPharmaceutical Preparations Industry84th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.00, Rocket Pharmaceuticals has a forecasted upside of 100.4% from its current price of $26.94.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.31% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 2.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 2.5 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 7 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows4 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,220,239.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -9.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesMarch 26, 2024 | insidertrades.comJohn Militello Sells 2,490 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockMarch 26, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director Sells $7,789,820.00 in StockMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 29, 2024 | msn.comSkyler Miser helps bring Ringling Bros. back to DCU Center with a bang as the Human RocketMarch 29, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Rating of "Buy" by AnalystsMarch 28, 2024 | americanbankingnews.comCritical Analysis: Rocket Pharmaceuticals (NASDAQ:RCKT) vs. Ironwood Pharmaceuticals (NASDAQ:IRWD)March 27, 2024 | investing.comRocket Pharmaceuticals director sells over $7.79 million in company stockMarch 26, 2024 | businesswire.comRocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership TeamMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 26, 2024 | finanznachrichten.deValworx, Inc.: The University of Alabama and Valworx Announce Partnership for Experimental Rocket ProjectMarch 25, 2024 | msn.comComedian Tom Segura set to play Rocket Mortgage FieldHouseMarch 22, 2024 | msn.comMystery in the sky: Rocket Lab launches US 'spy' satellite from VirginiaMarch 21, 2024 | msn.comRocket Lab launches mysterious spy satellites in 4th-ever US liftoff (video)March 21, 2024 | usnews.comJapan’s Space Agency Says It Hopes to Forge a Profitable Launch Business With Its New H3 RocketMarch 19, 2024 | forbes.comRocket Pharmaceuticals Shines Spotlight On Rare DiseasesMarch 18, 2024 | msn.comCanadiens send defenceman David Reinbacher to Laval RocketMarch 18, 2024 | usnews.comNorth Korea's Kim Oversees Firing Drills With 'Super-Large' Rocket Launchers, State Media SaysMarch 18, 2024 | msn.comMontreal Canadiens assign defensive prospect David Reinbacher to AHL's Laval RocketMarch 14, 2024 | msn.comJennifer Lopez 2024 tour stop canceled in Cleveland: Show called off at Rocket Mortage FieldHouseMarch 12, 2024 | msn.comParents, lawmakers voice opinions on U.S. Space and Rocket Center transgender employeeMarch 11, 2024 | msn.comShe went into the family business ... as the ‘Human Rocket’ in the circusFebruary 28, 2024 | yahoo.comRocket Lab has 'misrepresented' Neutron launch readiness, congressional memo saysFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rocket Pharmaceuticals Amidst Strategic Progress and Solid FinancialsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rocket Pharmaceuticals Amid Promising Pipeline and Upcoming Commercial LaunchFebruary 27, 2024 | finance.yahoo.comRCKT Apr 2024 17.500 putFebruary 26, 2024 | businesswire.comRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressFebruary 24, 2024 | msn.comRocket Racing Patch v28.30: New Speed Run Mode, ImprovementsSee More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today3/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees268Year Founded2018Price Target and Rating Average Stock Price Target$54.00 High Stock Price Target$65.00 Low Stock Price Target$47.00 Potential Upside/Downside+100.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.83% Return on Assets-45.87% Debt Debt-to-Equity Ratio0.04 Current Ratio7.80 Quick Ratio7.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book4.93Miscellaneous Outstanding Shares90,500,000Free Float62,357,000Market Cap$2.44 billion OptionableOptionable Beta1.08 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Gaurav D. Shah M.D. (Age 49)CEO & Director Comp: $1.05MMs. Kinnari Patel M.B.A. (Age 45)Pharm.D., President & COO Comp: $849.93kMr. John C. Militello CPA (Age 51)VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer Comp: $501.42kMr. Mayo Pujols (Age 55)Chief Technical Officer & Executive VP Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 50)Senior VP & Chief Business Officer Comp: $619.13kMr. Martin Louis Wilson J.D. (Age 48)General Counsel, Chief Compliance Officer & Senior VP Comp: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Senior VP & Chief Human Resources OfficerMr. Jonathan Schwartz M.D. (Age 59)Chief Gene Therapy Officer & Senior VP of Clinical Development Comp: $557.79kDr. Gayatri R. Rao J.D.M.D., Chief Development Officer of LVV & Senior VPMore ExecutivesKey CompetitorsTG TherapeuticsNASDAQ:TGTXKeros TherapeuticsNASDAQ:KROSRhythm PharmaceuticalsNASDAQ:RYTMAlpine Immune SciencesNASDAQ:ALPNCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 1,495 shares on 3/22/2024Ownership: 0.017%Gotham MakkerSold 274,000 sharesTotal: $7.79 M ($28.43/share)John MilitelloSold 2,490 sharesTotal: $69,969.00 ($28.10/share)Vanguard Group Inc.Bought 843,552 shares on 3/11/2024Ownership: 6.019%Wellington Management Group LLPBought 174,716 shares on 3/5/2024Ownership: 9.058%View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price target for 2024? 8 brokers have issued twelve-month price targets for Rocket Pharmaceuticals' shares. Their RCKT share price targets range from $47.00 to $65.00. On average, they predict the company's share price to reach $54.00 in the next year. This suggests a possible upside of 100.4% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2024? Rocket Pharmaceuticals' stock was trading at $29.97 on January 1st, 2024. Since then, RCKT shares have decreased by 10.1% and is now trading at $26.94. View the best growth stocks for 2024 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings data on Monday, February, 26th. The biotechnology company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.14. During the same period in the prior year, the company posted ($0.92) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).Franklin Genomic Advancements ETF (HELX). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.06%), Vanguard Group Inc. (6.04%), Vanguard Group Inc. (6.02%), Westfield Capital Management Co. LP (4.37%), Price T Rowe Associates Inc. MD (2.92%) and Price T Rowe Associates Inc. MD (2.92%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Martin Wilson and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RCKT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.